

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON NOVEMBER 23, 2021

The Board announces that, at the EGM held on November 23, 2021, the proposed resolution as set out in the notice of EGM dated November 4, 2021 was duly passed by the shareholders of the Company by way of poll.

References are made to the circular (the “**Circular**”) and the notice of extraordinary general meeting (the “**EGM**”) of WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司* (the “**Company**”) both dated November 4, 2021 in relation to the proposed adoption of the Subsidiary Share Option Schemes. Unless otherwise defined, terms used herein shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE EGM HELD ON NOVEMBER 23, 2021

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that at the EGM held on November 23, 2021, the proposed resolution as set out in the notice of EGM dated November 4, 2021 was duly passed by the shareholders of the Company by way of poll.

The poll results taken at the EGM were as follows:

| Ordinary Resolution | Number of Votes (Approximate %) | |
|--|------------------------------------|-------------------------|
| | For | Against |
| To approve the adoption of subsidiary share option schemes of WuXi Vaccines (Cayman) Inc. and WuXi XDC Cayman Inc., subsidiaries of the Company. ^(Note) | 2,292,472,141 (71.53%) | 912,369,987 (28.47%) |

Note: The full text of the resolution is set out in the notice of EGM.

As at the date of the EGM, the total number of shares of the Company in issue was 4,248,372,787 Shares, being the total number of shares entitling the holders thereof to attend and vote on the resolution proposed at the EGM.

There were no restrictions on any shareholders of the Company to cast votes on the resolution proposed at the EGM. No shareholder of the Company has stated his/her/its intention in the Circular to vote against or to abstain from voting on the resolution at the EGM.

The Company's Hong Kong branch share registrar, Tricor Investor Services Limited, was appointed as the scrutineer for the vote-taking at the EGM.

For and on behalf of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, November 23, 2021

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Ning Zhao, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Kenneth Walton Hitchner III as independent non-executive Directors.

* *For identification purpose only*